scholarly journals Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

2016 ◽  
Vol 49 (5) ◽  
pp. 1991-2000 ◽  
Author(s):  
Kaizhou Jin ◽  
Jin Xu ◽  
Jie Chen ◽  
Minhu Chen ◽  
Rufu Chen ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Surgical Management ◽  
Neuroendocrine Tumors ◽  
Neuroendocrine Neoplasms ◽  
Study Group ◽  
Synchronous Liver Metastasis ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Chinese Study

scholarly journals Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 919
Author(s):  
Koichiro Kimura ◽  
Junichi Tsuchiya ◽  
Yoshio Kitazume ◽  
Mitsuhiro Kishino ◽  
Keiichi Akahoshi ◽  
...  
Keyword(s):  
Critical Role ◽  
Neuroendocrine Neoplasms ◽  
Enhancement Ratio ◽  
Dynamic Ct ◽  
Synchronous Liver Metastasis ◽  
Enhancement Pattern ◽  
Pax6 Expression ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Dynamic Enhancement ◽  
Ct Features

Paired box 6 (PAX6) is a transcription factor that plays a critical role in tumor suppression, implying that the downregulation of PAX6 promotes tumor growth and invasiveness. This study aimed to examine dynamic computed tomography (CT) features for predicting pancreatic neuroendocrine neoplasms (Pan-NENs) with low PAX6 expression. We retrospectively evaluated 51 patients with Pan-NENs without synchronous liver metastasis to assess the pathological expression of PAX6. Two radiologists analyzed preoperative dynamic CT images to determine morphological features and enhancement patterns. We compared the CT findings between low and high PAX6 expression groups. Pathological analysis identified 11 and 40 patients with low and high PAX6 expression, respectively. Iso- or hypoenhancement types in the arterial and portal phases were significantly associated with low PAX6 expression (p = 0.009; p = 0.001, respectively). Low PAX6 Pan-NENs showed a lower portal enhancement ratio than high PAX6 Pan-NENs (p = 0.044). The combination based on enhancement types (iso- or hypoenhancement during arterial and portal phases) and portal enhancement ratio (≤1.22) had 54.5% sensitivity, 92.5% specificity, and 84.3% accuracy in identifying low PAX6 Pan-NENs. Dynamic CT features, including iso- or hypoenhancement types in the arterial and portal phases and lower portal enhancement ratio may help predict Pan-NENs with low PAX6 expression.

scholarly journals Surgical management of pancreatic neuroendocrine neoplasms

2014 ◽  
Vol 34 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Stefano Partelli ◽  
Angela Maurizi ◽  
Domenico Tamburrino ◽  
Stefano Crippa ◽  
Silvia Pandolfi ◽  
...  
Keyword(s):  
Surgical Management ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms

Analysis of survival after surgical management of pancreatic neuroendocrine neoplasms (PNENs) in a single center

Pancreatology ◽  
2017 ◽  
Vol 17 (4) ◽  
pp. S28
Author(s):  
Junli Wu ◽  
Wenbin Xu ◽  
Jishu Wei ◽  
Kai Zhang ◽  
Xinchun Liu ◽  
...  
Keyword(s):  
Surgical Management ◽  
Neuroendocrine Neoplasms ◽  
Single Center ◽  
Pancreatic Neuroendocrine Neoplasms

scholarly journals Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maoen Pan ◽  
Yuanyuan Yang ◽  
Tianhong Teng ◽  
Fengchun Lu ◽  
Yanchan Chen ◽  
...  
Keyword(s):  
Logistic Regression ◽  
High Risk ◽  
Liver Metastasis ◽  
Characteristic Curve ◽  
Calibration Plot ◽  
Neuroendocrine Neoplasms ◽  
Multivariate Logistic Regression ◽  
Discriminative Ability ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Good Ability

Abstract Background Liver metastasis is an important prognostic factor for pancreatic neuroendocrine neoplasms (pNENs), but the relationship between the clinical features of patients with pNEN and liver metastasis remains undetermined. The aim of this study was to establish and validate an easy-to-use nomogram to predict liver-metastasis in patients with pNEN. Methods We obtained the clinicopathologic data of 2960 patients with pancreatic neuroendocrine neoplasms from the Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2016. Univariate and multivariate logistic regression were done to screen out independent influencing factors to establish the nomogram. The calibration plots and the area under the receiver operating characteristic curve (AUC) were used to evaluate the performance of nomogram. Decision curve analysis (DCA) was applied to compare the novel model with the conventional predictive methods. Results A total of 2960 patients with pancreatic neuroendocrine neoplasms were included in the study. Among these, 1974 patients were assigned to the training group and 986 patients to the validation group. Multivariate logistic regression identified, tumor size, grade, other site metastasis, T stage and N stage as independent risk factors. The calibration plot showed good discriminative ability in the training and validation groups, with C-indexes of 0.850 for the training cohort and 0.846 for the validation cohort. The AUC values were 0.850 (95% CI 0.830–0.869) and 0.839 (95% CI 0.812–0.866), respectively. The nomogram total points (NTP) had the potential to stratify patients into low risk, medium risk and high risk (P < 0.001). Finally, comparing the nomogram with traditional prediction methods, the DCA curve showed that the nomogram had better net benefit. Conclusions Our nomogram has a good ability to predict liver metastasis of pancreatic neuroendocrine neoplasms, and it can guide clinicians to provide suitable prevention and treatment measures for patients with medium- and high-risk liver metastasis.

scholarly journals Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls

2021 ◽  
Author(s):  
Björn Konukiewitz ◽  
Moritz Jesinghaus ◽  
Atsuko Kasajima ◽  
Günter Klöppel
Keyword(s):  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Molecular Profile ◽  
Neuroendocrine Neoplasms ◽  
Histological Differentiation ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Diagnostic Pitfalls ◽  
Neuroendocrine Carcinomas

AbstractCommon to neuroendocrine neoplasms of the pancreas is their expression of synaptophysin, chromogranin A, and/or INSM1. They differ, however, in their histological differentiation and molecular profile. Three groups can be distinguished: well-differentiated neuroendocrine neoplasms (neuroendocrine tumors), poorly differentiated neuroendocrine neoplasms (neuroendocrine carcinomas), and mixed neuroendocrine-non-neuroendocrine neoplasms. However, the expression of synaptophysin and, to a lesser extent, also chromogranin A is not restricted to the neuroendocrine neoplasms, but may also be in a subset of non-neuroendocrine epithelial and non-epithelial neoplasms. This review provides the essential criteria for the diagnosis of pancreatic neuroendocrine neoplasms including diagnostic clues for the distinction of high-grade neuroendocrine tumors from neuroendocrine carcinomas and an algorithm avoiding diagnostic pitfalls in the delineation of non-neuroendocrine neoplasms with neuroendocrine features from pancreatic neuroendocrine neoplasms.

scholarly journals What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5954
Author(s):  
Samuel Frey ◽  
Eric Mirallié ◽  
Maëlle Le Bras ◽  
Nicolas Regenet
Keyword(s):  
Surgical Management ◽  
Recent Literature ◽  
Pancreatic Insufficiency ◽  
Neuroendocrine Differentiation ◽  
Narrative Review ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Hereditary Syndromes ◽  
Wait And See

Pancreatic neuroendocrine neoplasms (panNENs) are a heterogeneous group of tumors derived from cells with neuroendocrine differentiation. They are considered malignant by default. However, their outcomes are variable depending on their presentation in the onset of hereditary syndromes, hormonal secretion, grading, and extension. Therefore, although surgical treatment has long been suggested as the only treatment of pancreatic neuroendocrine neoplasms, its modalities are an evolving landscape. For selected patients (small, localized, non-functional panNENs), a “wait and see” strategy is suggested, as it is in the setting of multiple neuroendocrine neoplasia type 1, but the accurate size cut-off remains to be established. Parenchyma-sparring pancreatectomy, aiming to limit pancreatic insufficiency, are also emerging procedures, which place beyond the treatment of insulinomas and small non-functional panNENs (in association with lymph node picking) remains to be clarified. Furthermore, giving the fact that the liver is generally the only metastatic site, surgery keeps a place of choice alongside medical therapies in the treatment of metastatic disease, but its modalities and extensions are still a matter of debate. This narrative review aims to describe the current recommended surgical management for pancreatic NENs and controversies in light of the actual recommendations and recent literature.

scholarly journals AB101. P75. Surgical management of pancreatic neuroendocrine neoplasms (PNENs) in a single center

2018 ◽  
Vol 1 (1) ◽  
pp. AB101-AB101
Author(s):  
Junli Wu ◽  
Wenbin Xu ◽  
Jishu Wei ◽  
Kai Zhang ◽  
Xinchun Liu ◽  
...  
Keyword(s):  
Surgical Management ◽  
Neuroendocrine Neoplasms ◽  
Single Center ◽  
Pancreatic Neuroendocrine Neoplasms
Sign in / Sign up

Export Citation Format

Share Document